Showing 7941-7950 of 8822 results for "".
- InMode: New EmbraceRF Solution Introduces Subdermal Adipose Remodelinghttps://practicaldermatology.com/news/inmode-new-embracerf-solution-introduces-subnormal-adipose-remodeling/2457733/Introducing the concept of Subdermal Adipose Remodeling, InMode Aesthetic Solutions is launching EmbraceRF to target the neck and face through a powerful combination of
- Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumabhttps://practicaldermatology.com/news/opdivo-data-superior-recurrence-free-survival-versus-ipilimumab/2457734/Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) in patients with stage IIIB/C or stage IV melanoma who are at high ri
- Avon Receives Patents for Rotational Infinite Effects Skincare Technologyhttps://practicaldermatology.com/news/avon-receives-patents-for-rotational-infinite-effects-skincare-technology/2457739/Avon has been issued two new patents for new technology currently included in the ANEW Reversalist Infinite Effects and most recently the ANEW Ultimate Infinite Effects products. The rotational regimen is designed to
- Eclipse Announces New Board Membershttps://practicaldermatology.com/news/eclipse-announces-new-board-members/2457740/Meet Eclipse’s Medical and Scientific Advisory Board (M&SAB) for 2018. The 2018 Eclipse M&SAB includes: Dr. Sanjay Batra Dr. Batra obtained his PhD in physiology from the University of Ottawa, C
- DermTech: Carcinome Clinical Study Enrollment Completehttps://practicaldermatology.com/news/dermtech-carcinome-clinical-study-enrollment-complete/2457745/DermTech, Inc., the global leader in non-invasive molecular dermatology, announced completion of enrollment in the Carcinome™ clinical study. The goal of the Carcinome™ study is to develop a non-invasive genomic test to differentiate basal cell carcinoma (BCC) and squamous cell
- Skincare on Trial: Revision Introduces New Patient-Friendly Optionhttps://practicaldermatology.com/news/skincare-on-trial-revision-introduces-new-patient-friendly-option/2457752/Revision Skincare has introduced a collection of five comprehensive 45-day trial regimens they say are designed to address the needs of
- Greater Skin Cancer Risk Seen in U.S. Military Personnelhttps://practicaldermatology.com/news/greater-skin-cancer-risk-seen-in-us-military-personnel/2457762/U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD). The f
- FDA Frowns on Evolus' Botox Rivalhttps://practicaldermatology.com/news/fda-frowns-on-evolus-botox-rival/2457763/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat
- Innovations in Skin of Color Dermatology Award Goes to Eliot Battle, MDhttps://practicaldermatology.com/news/innovations-in-skin-of-color-dermatology-award-goes-to-eliot-battle-md/2457775/Eliot Battle, MD has been awarded the Innovations in Skin of Color Dermatology Award. The award was presented by The&nbs